Dr. Gordon Koon-Man Mak, MD

Dr. Mak practices at San Mateo Medical Center in San Mateo, California, part of County of San Mateo, California.

Dr. Mak's NPI, 1447330725, was assigned on October 17, 2006. Dr. Mak graduated from David Geffen School of Medicine at UCLA in 1995. Dr. Mak holds California license A61568.

Dr. Mak's primary practice is San Mateo Medical Center, at 222 W 39th Ave, San Mateo, CA 94403 in San Mateo County. The practice phone is (650) 573-2222.

Dr. Mak's primary practice is San Mateo Medical Center in San Mateo, California, part of County of San Mateo, California. Dr. Mak is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is San Mateo Medical Center. Dmand AI also links Dr. Mak to 1 more hospital, 1 skilled nursing facility and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mak practices, 4 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mak's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mak is board certified in critical care medicine by the American Board of Internal Medicine. Dr. Mak is licensed in California.

Dmand AI lists asthma, chronic obstructive pulmonary disease (COPD), pleural effusion, pneumonia, pulmonary fibrosis, sleep apnea and tobacco use among the conditions Dr. Mak treats.

CMS data shows 212 Medicare services from Dr. Mak across 5 procedure codes in 2024, for 159 Medicare patients. Medicare paid $13,029 for them.

CMS counts 159 Medicare patients who saw Dr. Mak in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 45% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mak's median patient age at 64, with 56% women.

In 2024, Dr. Mak wrote 865 Medicare Part D claims for 136 patients. 37% of them were for generic drugs. CMS names the drug for 775 of them, across 20 drugs with 11 or more claims each, at $406,090 in total drug cost. In 2023, CMS named 840 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Mak for performance year 2024, reported as part of a group. Dr. Mak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mak as offering telehealth.

Dmand AI links 4 papers to Dr. Mak in 2005. The most frequent topics are Pulmonary Disease, Chronic Obstructive. Dr. Mak's most frequent co-authors are Gerald J. Berry, MD, Michael Keith Gould, MD, MS and Brian M. Haus, MD.

CMS Open Payments shows 22 general payments to Dr. Mak from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $600.

Dr. Mak graduated from David Geffen School of Medicine at UCLA in 1995.

Dr. Mak is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.